Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00974233 · ClinicalTrials.gov registry record · Phase 2

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

A Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 2
Development phase
34
Enrollment target
10
Study locations

NCT00974233 is a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 34 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (81% lower). The trial reports 10 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00974233, a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 2
Development phase
34 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Interventions

  • DRUG Rituximab
  • DRUG Lenalidomide
  • DRUG Bendamustine

Study Locations (10)

Wisconsin

  • St Vincent Regional Cancer Center - Green Bay
  • Bellin Memorial Hospital - Green Bay
  • Mercy Health System Heme/Onc - Janesville
  • Gundersen Clinic - La Crosse
  • University of Wisconsin Carbone Cancer Center - Madison
  • Marshfield Clinic - Marshfield
  • Medical College of Wisconsin - Milwaukee
  • Oconomowoc Memorial Hospital - Oconomowoc
  • Waukesha Memorial Hospital - Waukesha
  • Riverview Hospital - Wisconsin Rapids

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2009-10
Est. Completion 2015-04
Phase Phase 2

Sponsor

University of Wisconsin, Madison

1,039 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00974233

The ClinicalTrials.gov registry entry for NCT00974233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (81% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.

NCT00974233 reports 10 study locations spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT00974233 about?

NCT00974233 is a clinical study titled "Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL". The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill). The purpose of this study is t...

What is the current status of trial NCT00974233?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2009-10. Estimated completion is 2015-04.

What conditions does trial NCT00974233 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

What interventions are being tested in trial NCT00974233?

The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG), Bendamustine (DRUG).

Who is sponsoring clinical trial NCT00974233?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00974233 being conducted?

This trial has 10 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Small Lymphocytic Lymphoma

All registered trials for this condition

Wisconsin

All trials with a study site in Wisconsin

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.